Genotypic analysis of genes associated with independent resistance and cross-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7805-7810

  Rueda, Johana ^a,b   Realpe, Teresa ^a,b   Mejia, Gloria Isabel ^b   Zapata, Elsa ^b   Rozo, Juan Carlos ^c   Ferro, Beatriz Eugenia ^c,d   Robledo, Jaime ^a,b  

^a UNIVERSIDAD PONTIFICIA BOLIVARIANA   (Colombia)

^b Corporación para Investigaciones Biológicas ^*  (Colombia)

^c CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL PROTEIN; ETHA PROTEIN; ETHIONAMIDE; INHA PROTEIN; ISONIAZID; KATG PROTEIN; MSHA PROTEIN; NDH PROTEIN; UNCLASSIFIED DRUG; CATALASE; ETHR PROTEIN, MYCOBACTERIUM TUBERCULOSIS; FIMBRIA PROTEIN; INHA PROTEIN, MYCOBACTERIUM; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REPRESSOR PROTEIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL MUTATION; BACTERIUM ISOLATE; CROSS RESISTANCE; DNA SEQUENCE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; FIMBRIAE PROTEINS; GENOTYPE; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NADH DEHYDROGENASE; OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84954502020     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01028-15     Document Type: Article

References (43)

1. World Health Organization. 2014. Nineteenth global report on tuberculosis. Report number WHO/HTM/TB/2014.08. World Health Organization, Geneva, Switzerland.
2. Vale N, Gomes P, Santos HA. 2013. Metabolism of the antituberculosis drug ethionamide. Curr Drug Metab 14:151-158. http://dx.doi.org/10.2174/138920013804545151.
3. De La Iglesia AI, Morbidoni HR. 2006. Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends. Rev Argent Microbiol 38:97-109. (In Spanish.)
4. Vilchèze C, Jacobs WR, Jr. 2014. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectrum 2:MGM2-0014-2013. http://dx.doi.org/10.1128/microbiolspec.MGM2-0014-2013.
5. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, De Lisle G, Jacobs WR, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230. http://dx.doi.org/10.1126/science.8284673.
6. Lee H, Cho SN, Bang HE, Lee JH, Bai GH, Kim SJ. 2000. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Tuberc Lung Dis 4:441-447.
7. Imperiale BR, Di Giulio ÁB Adrián Cataldi A, Morcillo NS. 2014. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin, and levofloxacin with their respective structural analogs. J Antibiot 67:749-754. http://dx.doi.org/10.1038/ja.2014.61.
8. Machado D, Perdigão J, Ramos J, Couto I, Portugal I, Ritter C, Boettger EK, Viveiros M. 2013. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother 68: 1728-1732. http://dx.doi.org/10.1093/jac/dkt090.
9. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. 2011. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:355-360. http://dx.doi.org/10.1128/AAC.01030-10.
10. Boonaiam S, Chaiprasert A, Prammananan T, Leechawengwongs M. 2010. Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. Clin Microbiol Infect 16:396-399. http://dx.doi.org/10.1111/j.1469-0691.2009.02838.x.
11. Hazbón MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, León CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, Ponce de León A, Alland D. 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50:2640-2649. http://dx.doi.org/10.1128/AAC.00112-06.
12. Jagielski T, Grzeszczuk M, Kamiń ski M, Roeske K, Napiórkowska A, Stachowiak R, Augustynowicz-Kopeć E, Zwolska Z, Bielecki J. 2013. Identification and analysis of mutations in the katG gene in multidrugresistant Mycobacterium tuberculosis clinical isolates. Pneumonol Alergol Pol 81:298-307.
13. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE, III. 2000. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 97:9677-9682. http://dx.doi.org/10.1073/pnas.97.17.9677.
14. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. 2003. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 47:3799-3805. http://dx.doi.org/10.1128/AAC.47.12.3799-3805.2003.
15. Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbón MH, Alland D, Sacchettini JC, Jacobs WR, Jr. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 46:453-466. http://dx.doi.org/10.1046/j.1365-2958.2002.03162.x.
16. + ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 49:708-720. http://dx.doi.org/10.1128/AAC.49.2.708-720.2005.
17. Cardoso RF, Cardoso MA, Leite CQF, Sato DN, Mamizuka EM, Hirata RDC, Fiúza de Mello F, Hirata MH. 2007. Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil. Mem Inst Oswaldo Cruz 102:59-61. http://dx.doi.org/10.1590/S0074-02762007000100009.
18. Baulard AR, Betts JC, Engohang-Ndong J, Quan S, McAdam RA, Brennan PJ, Lochth C, Besra GS. 2000. Activation of the prodrug ethionamide is regulated in mycobacteria. J Biol Chem 275:28326-28331. http://dx.doi.org/10.1074/jbc.M003744200.
19. Vilchèze C, Av-Gay Y, Attarian R, Liu Z, Hazbón MH, Colangeli R, Chen B, Liu W, Alland D, Sacchettini JC, Jacobs WR, Jr. 2008. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol 69:1316-1329. http://dx.doi.org/10.1111/j.1365-2958.2008.06365.x.
20. Xu X, Vilchèze C, Av-Gay Y, Gómez-Velasco A, Jacobs WR, Jr. 2011. Precise null deletion mutations of the mycothiol synthesis genes reveal their role in isoniazid and ethionamide resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 55:3133-3139. http://dx.doi.org/10.1128/AAC.00020-11.
21. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, van Soolingen D. 2010. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48:2749-2753. http://dx.doi.org/10.1128/JCM.00652-10.
22. World Health Organization. 2010. Framework for Implementing New Tuberculosis Diagnostic. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/laboratory/whopolicyframework-july10-revnov10.pdf.
23. Lin S-YG, Desmond E, Bonato D, Gross W, Siddiqi S. 2009. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 47:3630-3624. http://dx.doi.org/10.1128/JCM.00803-09.
24. Asiko V. 2010. High ethionamide resistance in Mycobacterium tuberculosis strains isolated in Kenya. Int J Infect Dis 14(Suppl):e309. http://dx.doi.org/10.1016/j.ijid.2010.02.2172.
25. Dalal A, Pawaskar A, Das M, Desai R, Prabhudesai P, Chhajed P, Rajan S, Reddy D, Babu S, Jayalakshmi TK, Saranchuk P, Rodrigues C, Isaakidis P. 2015. Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time. PLoS One 10:e0116798. http://dx.doi.org/10.1371/journal.pone.0116798.
26. Günther G, Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Pontali E, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET. 2015. Multidrug-resistant tuberculosis in Europe, 2010 to 2011. Emerg Infect Dis 21:409-416. http://dx.doi.org/10.3201/eid2103.141343.
27. National Institute of Health, Colombia. 2013. Guidelines for programmatic management of patients with drug-resistant tuberculosis. National Institute of Health, Bogota, Colombia.
28. Becerril-Montes P, Said-Fernández S, Luna-Herrera J, Caballero-Olín G, Enciso-Moreno JA, Martínez-Rodríguez HG, Padilla-Rivas G, Nancy-Garza-Treviño E, Molina-Salinas GM. 2013. A population-based study of first- and second-line drug-resistant tuberculosis in a highburden area of the Mexico/United States border. Mem Inst Oswaldo Cruz 108:160-166. http://dx.doi.org/10.1590/0074-0276108022013006.
29. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard-2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
30. van Soolingen D, de Haas PE, Hermans PW, van Embden JD. 1994. DNA fingerprinting of Mycobacterium tuberculosis. Methods Enzymol 235:196-205. http://dx.doi.org/10.1016/0076-6879(94)35141-4.
31. Krüüner A, Yates MD, Drobniewski FA. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of firstand second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 44:811-818. http://dx.doi.org/10.1128/JCM.44.3.811-818.2006.
32. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against secondline drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 12:1449-1455.
33. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. 2000. Genomic mutations in the katG, inhA, and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuberc Lung Dis 80:47-56. http://dx.doi.org/10.1054/tuld.1999.0231.
34. Ferro BE, García PK, Nieto LM, Van Soolingen D. 2013. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. J Clin Microbiol 51:2220-2224. http://dx.doi.org/10.1128/JCM.00429-13.
35. Silva MS, Senna SG, Ribeiro MO, Valim ARM, Telles MA, Kritski A, Morlock GP, Cooksey RC, Zaha A, Rossetti MLR. 2003. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 41:4471-4474. http://dx.doi.org/10.1128/JCM.41.9.4471-4474.2003.
36. García de Viedma D, Díaz Infantes MS, Lasala F, Chaves F, Alcalá L, Bouza E. 2002. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol 40:988-995. http://dx.doi.org/10.1128/JCM.40.3.988-995.2002.
37. Abe C, Kobayashi I, Mitarai S, Wada M, Kawabe Y, Takashima T, Suzuki K, Sng LH, Wang S, Htay HH, Ogata H. 2008. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol 46:2263-2268. http://dx.doi.org/10.1128/JCM.00561-08.
38. Rouse DA, Li Z, Bai GH, Morris SL. 1995. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 39:2472-2477. http://dx.doi.org/10.1128/AAC.39.11.2472.
39. Zhao X, Yu H, Yu S, Wang F, Sacchettini JC, Magliozzo RS. 2006. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (katG) and its S315T mutant. Biochemistry 45:4131-4140. http://dx.doi.org/10.1021/bi051967o.
40. + binding proteins in mycobacterial INH resistance. Infect Immun 66:5099-5106.
41. Projahn M, Köser CU, Homolka S, Summers DK, Archer JAC, Niemann S. 2011. Polymorphisms in isoniazid and prothionamide resistance genes of the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 55: 4408-4411. http://dx.doi.org/10.1128/AAC.00555-11.
42. Abate D, Tedla Y, Meressa D, Ameni G. 2014. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis 18:946-951. http://dx.doi.org/10.5588/ijtld.13.0926.
43. Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, NcNeil M, Peterson SN, Chatterjee D, Fleischmann R, Alland D. 2013. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 45:1190-1197. http://dx.doi.org/10.1038/ng.2743.